

REMARKS

Claims 6-9, 14-23, and 30 are pending and rejected.

Correction of amendments to claim 6 have been made to underline the word

"B-1,4-endoglucanase".

No new matter has been added by this amendment.

CONCLUSION


Applicants point out that the above remarks and amendments overcome the rejections. Reconsideration of the application and allowance of all pending claims is earnestly solicited.

Should the Examiner wish to discuss any of the above in greater detail or deem that further amendments should be made to improve the form of the claims, the Examiner is invited to telephone the undersigned at the Examiner's convenience.

Respectfully submitted,

Syngenta Biotechnology, Inc.
3054 E. Cornwallis Road
Research Triangle Park, NC 27709-2257

Date: August 24, 2005


Mary Kakefuda
Attorney for Applicants
Registration No. 39,245
Telephone: 919-765-5071



Attorney Docket No. S-21043B
Serial No. 09/901,737

FILING BY "FIRST CLASS MAIL" UNDER 37 C.F.R. § 1.8

I hereby certify that the following correspondence is being deposited with the United States Postal Service as "First Class Mail" with proper postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, Alexandria, VA 22313-1450, on August 24, 2005.

- 1) Response to Notice of Non-Compliant Amendment – 4 pages
- 2) Return Postcard

Melissa Hardy

Name

Signature